Tonix Pharmaceuticals Holding Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNXP research report →
Range $18 – $27
Price Chart
About the company
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort.
- CEO
- Seth Lederman
- IPO
- 2012
- Employees
- 142
- HQ
- Berkeley Heights, NJ, US
Get TickerSpark's AI analysis on TNXP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.25M
- P/E
- -0.19
- PEG
- -0.00
- P/S
- 1.07
- P/B
- 0.22
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
- Gross Margin
- 86.91%
- Op Margin
- -436.25%
- Net Margin
- -420.45%
- ROE
- -80.97%
- ROIC
- -93549.80%
Latest fiscal year · YoY change
- Revenue
- $13.11M+29.8%
- Gross Profit
- $4.54M+95.0%
- Op Income
- $-125,703,000
- Net Income
- $-124,021,000+4.6%
- EPS
- $-14.57+91.7%
- OCF Growth
- -63.9%
- FCF Growth
- -69.1%
- 52W High
- $20.56
- 52W Low
- $2.30
- 50D MA
- $6.72
- 200D MA
- $11.45
- Beta
- 1.90
- RSI (14)
- 11
- Avg Volume
- 838.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tonix reported strong early TONMYA launch momentum, with third-quarter net sales of about $15 million and prescriptions up 28% quarter over quarter, while also advancing multiple pipeline programs and flagging an ANDA patent challenge.· November 9, 2026
- TONMYA third-quarter net sales were about $15 million, up 37% quarter over quarter, helped by payer agreements and a larger sales force.
- TONMYA prescriptions reached 16,400 in the quarter, up 28% sequentially; new prescriptions rose 17% and refills rose 56%.
- Coverage for TONMYA now reaches about 53% of U.S. covered lives, and management said approval rates are improving while bridge scripts are becoming a smaller share of total scripts.
- Tonix received notice of a Dr. Reddy’s ANDA Paragraph 4 challenge on TONMYA and said it will vigorously defend the IP; management said core patents currently protect into 2034.
- The company said its cash of $162.8 million at quarter-end, plus post-quarter equity proceeds, should fund operations and capex into early third quarter of 2027.
Net product revenue for Q3 2026 was approximately $17.2 million, versus $3.3 million in Q3 2025. That included about $15 million from TONMYA and $2.2 million from ZEMBRACE, SymTouch, and TOSYMRA. TONMYA net sales increased 37% quarter over quarter; prescriptions were 16,400, up 28% sequentially; new prescriptions rose 17%; and refill prescriptions rose 56%. Gross profit detail was not provided, but cost of sales was approximately $1.3 million versus $1.4 million a year ago. R&D expense was approximately $25.8 million versus $9.3 million last year, and SG&A was approximately $45.6 million versus $25.7 million last year. Cash and equivalents were approximately $162.8 million at September 30, 2026, down from $207.6 million at December 31, 2025. Management said cash plus post-quarter equity proceeds should fund operations and capex into early Q3 2027.
Seth Lederman emphasized that TONMYA is the company’s main value driver and said the launch is gaining traction with a larger sales force, improving payer access, and growing awareness among prescribers. He described the ANDA filing as a common generic challenge and said Tonix will defend its intellectual property vigorously, while noting current core patent protection into 2034. On the pipeline, he framed Horizon in MDD, TRAIL in Lyme prevention, and TNX-1500 in kidney transplant rejection as key strategic programs that could expand the company’s platform.
Bradley Saenger said quarter-end cash and equivalents were approximately $162.8 million, and that cash plus expected post-quarter equity proceeds should carry the company into early Q3 2027. He detailed the quarter’s cost structure: cost of sales of approximately $1.3 million, R&D of $25.8 million, and SG&A of $45.6 million, with SG&A driven mainly by launch-related sales and marketing spend and the expanded sales force. He also noted that a significant portion of SG&A was tied to the commercialization buildout for TONMYA and said that as the launch continues, this remains a significant part of SG&A.
Analysts focused on TONMYA durability, the drivers of sequential growth, bridge-to-covered conversion, and how the 150-person sales force is changing prescriber behavior. Management said anecdotal feedback suggests good efficacy and strong tolerability, with doctors describing some patients as seeing the drug as “life changing,” and said refills, new writers, and total writers are all increasing. On pricing and mix, management said revenue outpaced script growth because of gross-to-net dynamics, a better mix toward 60-count bottles, and improving payer approvals; bridge scripts are falling as coverage expands. Questions also covered the Dr. Reddy’s patent challenge, Lyme trial timing, and capital needs, with management reiterating that litigation details are limited, the Lyme study should start in the first quarter of 2027, and the company is watching expenses closely while still exploring partnerships.
The call showed clear launch momentum for TONMYA, with sequential growth in sales, prescriptions, refills, and writer activity alongside improving coverage and payer approvals. Management sounded confident that the expanded sales force, stronger awareness, and early durability signals can support continued growth into 2027.
TONMYA now faces an ANDA Paragraph 4 challenge from Dr. Reddy’s, and management acknowledged generic litigation as a real risk even while arguing the patents run into 2034. The company is also spending heavily to support the launch and pipeline, with R&D and SG&A both rising sharply year over year, and it still expects to need its cash resources and equity proceeds to fund operations only into early Q3 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 19.43M
- Float Shares
- 19.36M
of shares held by institutions
109 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.56M | ▲ 165.09K |
| Point72 Asset Management, L.P. | 1.12M | ▼ 50.30K |
| Millennium Management LLC | 818.78K | ▼ 148.15K |
| Vanguard Capital Management LLC | 691.89K | 0 |
| Vanguard Group Inc | 673.61K | ▲ 116.65K |
| Aqr Capital Management LLC | 670.80K | ▼ 211.79K |
| Jones Hill Capital LP | 563.74K | ▼ 61.69K |
| Logos Global Management LP | 550.00K | ▲ 550.00K |
| Geode Capital Management, LLC | 425.18K | ▲ 29.92K |
| Citadel Advisors LLC | 337.43K | ▲ 141.57K |
| State Street Corp | 335.08K | ▲ 63.71K |
| Essex Investment Management Co LLC | 292.40K | ▲ 127.25K |
Held by 107 ETFs
Biggest fund positions in TNXP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | LEDERMAN SETH | buy | 5,000 |
| Feb 24, 27 | Englese Thomas | other | 0 |
| May 13, 26 | Englese Thomas | other | 0 |
| Feb 25, 26 | Englese Thomas | other | 0 |
| Sep 4, 26 | Englese Thomas | other | 0 |
| Sep 9, 25 | Englese Thomas | other | 0 |
| Aug 27, 26 | LEDERMAN SETH | buy | 2,000 |
| Aug 20, 26 | BAGGER RICHARD H | buy | 1,000 |
| Jun 30, 26 | SAENGER BRADLEY | other | 1,453 |
| Jun 12, 26 | Taylor Carolyn E. | buy | 1,415 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNXP coverage
Recent articles, reports, and earnings notes.
Want a deeper read on TNXP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Tonix Pharmaceuticals' TONMYA Sales Jump 37% as Insurance Coverage Expands
marketbeat.com · Nov 10
Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Tonix Pharmaceuticals (TNXP) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights
globenewswire.com · Nov 9
Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 4
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
globenewswire.com · Nov 2
Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
globenewswire.com · Oct 27
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
globenewswire.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
